1999
DOI: 10.1001/archopht.117.4.493
|View full text |Cite
|
Sign up to set email alerts
|

Human Conjunctival Mast Cells

Abstract: To characterize the expression and regulation of conjunctival mast cell surface receptors important in allergic inflammation. Methods: Mast cells were isolated from human conjunctival tissues of cadavers. Mast cell surface markers were identified using flow cytometry with antibodies to IgE, Fc⑀RI, c-kit, and intercellular adhesion molecule-1 (ICAM-1). We evaluated the effect of 24-hour tumor necrosis factor ␣ (TNF-␣) or interleukin 4 (IL-4) incubation on the expression of mast cell c-kit, ICAM-1, and surface-b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2002
2002
2021
2021

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(3 citation statements)
references
References 19 publications
0
3
0
Order By: Relevance
“…Histamine, one of the main mediators of ocular allergy, has a stimulating effect on conjunctival fibroblasts and epithelial cells, inciting the production and expression of pro‐inflammatory cytokines, IL‐1, ‐6, ‐8, adhesion molecules and pro‐collagens, highlighting once again the ever‐broadening role of histamine in the pathogenesis of allergic conjunctival remodelling [5–8].…”
Section: Introductionmentioning
confidence: 99%
“…Histamine, one of the main mediators of ocular allergy, has a stimulating effect on conjunctival fibroblasts and epithelial cells, inciting the production and expression of pro‐inflammatory cytokines, IL‐1, ‐6, ‐8, adhesion molecules and pro‐collagens, highlighting once again the ever‐broadening role of histamine in the pathogenesis of allergic conjunctival remodelling [5–8].…”
Section: Introductionmentioning
confidence: 99%
“…The inhibition of c-kit positive mast cells by imatinib may be responsible for further exposure of the conjunctival mucosa to injuries. 14 Ophthalmic side effects have been shown to occur at higher imatinib dosages (600-800 mg/day) than at standard dosage (400 mg/day). Imatinib must be discontinued in patients with recurrent and Grade III and IV adverse effects.…”
Section: Discussionmentioning
confidence: 99%
“…Postulated mechanisms for epiphora include conjunctival chemosis resulting in ocular surface irritation and the overproduction of tears, lacrimal pump dysfunction due to periorbital edema, blockage of the puncta by conjunctival chalasis, and secretion of the medication in the tear film[20]. Hemorrhage in the conjunctiva reportedly affects up to 11% of imatinib-treated GIST patients and occurs in the absence of marrow suppression or in those with systemic bleeding tendency[21,22]. Genetic polymorphisms of EGFR , SLC22A1 , SLC22A5 , and ABCB1 may influence the imatinib-induced periorbital edema and conjunctival hemorrhage[22].…”
Section: Tki-associated Side Effectsmentioning
confidence: 99%